Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Insight Pharmaceuticals Corporation
WARNING LETTER
•Insight Pharmaceuticals Corporation

Insight Pharmaceuticals Corporation – FDA Warning Letter

Record Details

The FDA issued a Warning Letter to Insight Pharmaceuticals, LLC, regarding their drug product, "Auro Earache Relief Ear Drops," based on a review of its labeling and marketing information. The product is deemed misbranded under sections 502 and 503 of the FD&C Act and violates section 301.

The product's labeling, including its name and claims like "Relieves earache pain" and "temporary relief of pain, discomfort, and irritability associated with earaches," establishes it as a drug. Despite being marketed OTC, the FDA classifies it as a prescription drug under section 503(b)(1) because ear pain requires diagnosis and treatment by a physician, and it's not a recognized OTC indication in the final monograph for topical otic drug products (21 C.F.R. § 344).

Consequently, the product is misbranded under section 503(b)(4) for failing to bear the "Rx only" symbol and under section 502(f)(1) for lacking adequate directions for use, as the indication is not appropriate for OTC use. Furthermore, it is misbranded under section 502(a) because its labeling is false or misleading by representing the product as suitable for OTC treatment of a condition that requires professional diagnosis.

The FDA clarified that homeopathic drugs are subject to the same regulatory requirements as other drugs and must comply with section 5

Company
Insight Pharmaceuticals Corporation
Product type
Drugs
Office
Philadelphia District Office
Person
  • Kirk D. Sooter (District Director)
View Company Profile

ID · be60677d-6eb1-4e26-a1e6-a909d7d0a232

Violation Codes10
21 U.S.C. 353(b)(1)21 U.S.C. 35221 U.S.C. 35321 U.S.C. 33121 U.S.C. 321(g)(1)(B)21 U.S.C. 321(g)(1)(C)21 U.S.C. 353(b)(4)21 U.S.C. 352(f)(1)21 CFR 201.521 U.S.C. 352(a)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Insight Pharmaceuticals Corporation
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.